BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 7
• 8
• 9
• 10
• 11
• 14
• 15
• 16
• 17
• 18
• 21
• 22
• 23
• 28
• 29
• 30

• Drug Development

  Vasogen ACCLAIM Phase 3 Trial In Advanced Chronic Heart Failure Reaches Target Number Of Endpoint Events

  November 14, 2005

   · 

  5 min read
• Drug Development

  Abbott Laboratories Tricor Fails Main Goal In Diabetes Trial

  November 14, 2005

   · 

  1 min read
• Drug Development

  Roche Release: First Long Term Phase II Study Of CERA In Renal Patients Not Yet On Dialysis Showed Sustained And Stable Control Of Anemia

  November 14, 2005

   · 

  6 min read
• Drug Development

  ActivBiotics Announces Expansion Of Phase-3 PROVIDENCE-1 Study Of Antibiotic Treatment Of Patients With Peripheral Arterial Disease During World’s Largest Gathering Of Cardiovascular Disease Researchers

  November 14, 2005

   · 

  3 min read
• Drug Development

  Evotec OAI (Germany) Announces Initiation Of Phase I Clinic Trial With EVT 101

  November 14, 2005

   · 

  3 min read
• Deals

  Encore Medical Corporation Says To Be Bought By Compex Technologies, Inc. For $109 Million

  November 14, 2005

   · 

  5 min read
• Drug Development

  Keryx Biopharmaceuticals Announces Positive Final Results From Phase 2 Clinical Study For KRX-101 (Sulodexide Gelcaps) For The Treatment Of Diabetic Nephropathy

  November 14, 2005

   · 

  17 min read
• Drug Development

  Speedel Group Release: SPP301 Phase IIb Results In Diabetic Nephropathy Presented At ASN

  November 14, 2005

   · 

  10 min read
• Drug Development

  Schering-Plough Corporation Release: PEG-INTRON(R) And REBETOL(R) Combination Therapy Demonstrates Consistently High Response Rates Across Patient Weight Groups In ‘Real-Life’ Treatment Setting

  November 14, 2005

   · 

  9 min read
• Drug Development

  Shire Pharmaceuticals Group plc Release: New Six-year Data Supports FOSRENOL(R) As A Treatment Choice For End-Stage Renal Disease Patients

  November 14, 2005

   · 

  11 min read